Zentalis Pharmaceuticals Announces Board Changes and Filings
Ticker: ZNTL · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1725160
Sentiment: neutral
Topics: board-changes, executive-compensation, filing
Related Tickers: ZNTL
TL;DR
Zentalis board shakeup: Dr. Friedman out, new directors in, exec comp details filed.
AI Summary
On August 26, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the departure of Dr. Lori Friedman from its Board of Directors. Additionally, the report covers the election of new directors and updates regarding compensatory arrangements for certain officers. The filing also includes financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures can sometimes precede or accompany significant strategic shifts or financial adjustments.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Filer of the 8-K report
- Dr. Lori Friedman (person) — Departing Director
- August 26, 2025 (date) — Date of the earliest event reported
FAQ
Who has departed from Zentalis Pharmaceuticals' Board of Directors?
Dr. Lori Friedman has departed from the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated August 26, 2025.
What other items are covered in this 8-K filing besides director departures?
The filing also covers the election of directors, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
What is the Standard Industrial Classification for Zentalis Pharmaceuticals, Inc.?
The Standard Industrial Classification for Zentalis Pharmaceuticals, Inc. is PHARMACEUTICAL PREPARATIONS [2834].
What is the SEC file number for Zentalis Pharmaceuticals, Inc.?
The SEC file number for Zentalis Pharmaceuticals, Inc. is 001-39263.
Filing Stats: 721 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-08-26 16:08:57
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
Filing Documents
- zntl-20250826.htm (8-K) — 34KB
- ex991-clopressrelease.htm (EX-99.1) — 15KB
- image_0.jpg (GRAPHIC) — 67KB
- 0001725160-25-000154.txt ( ) — 277KB
- zntl-20250826.xsd (EX-101.SCH) — 2KB
- zntl-20250826_def.xml (EX-101.DEF) — 4KB
- zntl-20250826_lab.xml (EX-101.LAB) — 26KB
- zntl-20250826_pre.xml (EX-101.PRE) — 16KB
- zntl-20250826_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 26, 2025, the Company issued a press release related to the above-referenced transition, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and incorporated herein by reference. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on August 26, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: August 26, 2025 By: /s/ Julie Eastland Julie Eastland President and Chief Executive Officer